{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,15]],"date-time":"2026-10-15T12:01:13Z","timestamp":1792065673401,"version":"4.4.0"},"reference-count":61,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,9,1]],"date-time":"2019-09-01T00:00:00Z","timestamp":1567296000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100004325","name":"Astra Zeneca","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100004325","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","onlinecjc.ca","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Canadian Journal of Cardiology"],"published-print":{"date-parts":[[2019,9]]},"DOI":"10.1016\/j.cjca.2019.06.029","type":"journal-article","created":{"date-parts":[[2019,7,11]],"date-time":"2019-07-11T02:02:25Z","timestamp":1562810545000},"page":"1220-1227","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["The Use of Renin-Angiotensin System Inhibitors in Patients With Chronic Kidney Disease"],"prefix":"10.1016","volume":"35","author":[{"given":"Silvia J.","family":"Leon","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Navdeep","family":"Tangri","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cjca.2019.06.029_bib1","doi-asserted-by":"crossref","first-page":"E417","DOI":"10.1503\/cmaj.120833","article-title":"Prevalence estimates of chronic kidney disease in Canada: results of a nationally representative survey","volume":"185","author":"Arora","year":"2013","journal-title":"CMAJ"},{"key":"10.1016\/j.cjca.2019.06.029_bib2","doi-asserted-by":"crossref","first-page":"2073","DOI":"10.1016\/S0140-6736(10)60674-5","article-title":"Association of estimated glomerular filtration rate and albuminuria with all-cause and cardiovascular mortality in general population cohorts: a collaborative meta-analysis","volume":"375","author":"Matsushita","year":"2010","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2019.06.029_bib3","doi-asserted-by":"crossref","first-page":"101","DOI":"10.1038\/sj.jhh.1001960","article-title":"RAS inhibition in hypertension","volume":"20","author":"Ibrahim","year":"2006","journal-title":"J\u00a0Hum Hypertens"},{"key":"10.1016\/j.cjca.2019.06.029_bib4","doi-asserted-by":"crossref","first-page":"198","DOI":"10.1007\/s11906-000-0082-3","article-title":"Update: role of the angiotensin type-2 (AT(2)) receptor in blood pressure regulation","volume":"2","author":"Carey","year":"2000","journal-title":"Curr Hypertens Rep"},{"key":"10.1016\/j.cjca.2019.06.029_bib5","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1016\/j.peptides.2011.05.012","article-title":"New insights and perspectives on intrarenal renin-angiotensin system: focus on intracrine\/intracellular angiotensin II","volume":"32","author":"Zhuo","year":"2011","journal-title":"Peptides"},{"key":"10.1016\/j.cjca.2019.06.029_bib6","first-page":"1","article-title":"KDIGO 2012 clinical practice guideline for the evaluation and management of chronic kidney disease","volume":"3","year":"2013","journal-title":"Kidney Int Suppl"},{"key":"10.1016\/j.cjca.2019.06.029_bib7","first-page":"255","article-title":"Multicentre randomized controlled trial of angiotensin-converting enzyme inhibitor\/angiotensin receptor blocker withdrawal in advanced renal disease: the STOP-ACEI trial","volume":"31","author":"Bhandari","year":"2016","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cjca.2019.06.029_bib8","doi-asserted-by":"crossref","first-page":"2038","DOI":"10.1001\/jama.298.17.2038","article-title":"Prevalence of chronic kidney disease in the United States","volume":"298","author":"Coresh","year":"2007","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2019.06.029_bib9","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1161\/01.CIR.0000031732.78052.81","article-title":"Urinary albumin excretion predicts cardiovascular and noncardiovascular mortality in general population","volume":"106","author":"Hillege","year":"2002","journal-title":"Circulation"},{"key":"10.1016\/j.cjca.2019.06.029_bib10","doi-asserted-by":"crossref","first-page":"160","DOI":"10.1006\/enrs.1994.1052","article-title":"Proteinuria as a biomarker: risk of subsequent morbidity and mortality","volume":"66","author":"Wagener","year":"1994","journal-title":"Environ Res"},{"key":"10.1016\/j.cjca.2019.06.029_bib11","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1046\/j.1365-2249.2002.01979.x","article-title":"Leaked protein and interstitial damage in the kidney: is complement the missing link?","volume":"130","author":"Sheerin","year":"2002","journal-title":"Clin Exp Immunol"},{"key":"10.1016\/j.cjca.2019.06.029_bib12","doi-asserted-by":"crossref","first-page":"1341","DOI":"10.1038\/ki.2010.536","article-title":"Lower estimated glomerular filtration rate and higher albuminuria are associated with all-cause and cardiovascular mortality. A collaborative meta-analysis of high-risk population cohorts","volume":"79","author":"van der Velde","year":"2011","journal-title":"Kidney Int"},{"key":"10.1016\/j.cjca.2019.06.029_bib13","doi-asserted-by":"crossref","first-page":"939","DOI":"10.1016\/j.ekir.2018.04.004","article-title":"Change in albuminuria and risk of renal and cardiovascular outcomes: natural variation should be taken into account","volume":"3","author":"Smith","year":"2018","journal-title":"Kidney Int Rep"},{"key":"10.1016\/j.cjca.2019.06.029_bib14","doi-asserted-by":"crossref","first-page":"713","DOI":"10.1053\/j.ajkd.2014.01.416","article-title":"KDOQI US commentary on the 2012 KDIGO clinical practice guideline for the evaluation and management of CKD","volume":"63","author":"Inker","year":"2014","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cjca.2019.06.029_bib15","doi-asserted-by":"crossref","first-page":"1281","DOI":"10.1097\/01.hjh.0000431740.32696.cc","article-title":"2013 ESH\/ESC guidelines for the management of arterial hypertension: the Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC)","volume":"31","author":"Mancia","year":"2013","journal-title":"J\u00a0Hypertens"},{"key":"10.1016\/j.cjca.2019.06.029_bib16","doi-asserted-by":"crossref","first-page":"1553","DOI":"10.1001\/jama.2011.451","article-title":"A\u00a0predictive model for progression of chronic kidney disease to kidney failure","volume":"305","author":"Tangri","year":"2011","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2019.06.029_bib17","doi-asserted-by":"crossref","DOI":"10.1177\/2054358117705372","article-title":"Validation of the Kidney Failure Risk Equation in Manitoba","volume":"4","author":"Whitlock","year":"2017","journal-title":"Can J Kidney Health Dis"},{"key":"10.1016\/j.cjca.2019.06.029_bib18","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0198456","article-title":"Individual patient variability with the application of the kidney failure risk equation in advanced chronic kidney disease","volume":"13","author":"McCudden","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2019.06.029_bib19","doi-asserted-by":"crossref","first-page":"128","DOI":"10.1016\/S2213-8587(18)30314-0","article-title":"Change in albuminuria as a surrogate endpoint for progression of kidney disease: a meta-analysis of treatment effects in randomised clinical trials","volume":"7","author":"Heerspink","year":"2019","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cjca.2019.06.029_bib20","doi-asserted-by":"crossref","first-page":"S3","DOI":"10.2215\/CJN.03250807","article-title":"Slowing nephropathy progression: focus on proteinuria reduction","volume":"3","author":"Bakris","year":"2008","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cjca.2019.06.029_bib21","doi-asserted-by":"crossref","first-page":"385","DOI":"10.1016\/S2213-8587(14)70030-0","article-title":"Effects of sodium restriction and hydrochlorothiazide on RAAS blockade efficacy in diabetic nephropathy: a randomised clinical trial","volume":"2","author":"Kwakernaak","year":"2014","journal-title":"Lancet Diabetes Endocrinol"},{"key":"10.1016\/j.cjca.2019.06.029_bib22","doi-asserted-by":"crossref","first-page":"999","DOI":"10.1681\/ASN.2007060693","article-title":"Effects of dietary sodium and hydrochlorothiazide on the antiproteinuric efficacy of losartan","volume":"19","author":"Vogt","year":"2008","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.cjca.2019.06.029_bib23","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1053\/j.ajkd.2008.07.021","article-title":"Effect of renin-angiotensin-aldosterone system inhibition, dietary sodium restriction, and\/or diuretics on urinary kidney injury molecule 1 excretion in nondiabetic proteinuric kidney disease: a post hoc analysis of a randomized controlled trial","volume":"53","author":"Waanders","year":"2009","journal-title":"Am J Kidney Dis"},{"issue":"Suppl 1","key":"10.1016\/j.cjca.2019.06.029_bib24","first-page":"S1","article-title":"Diabetes Canada 2018 clinical practice guidelines for the prevention and management of diabetes in Canada","volume":"42","year":"2018","journal-title":"Can J Diabetes"},{"key":"10.1016\/j.cjca.2019.06.029_bib25","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1053\/j.ajkd.2017.12.007","article-title":"Management of traditional cardiovascular risk factors in CKD: what are the data?","volume":"72","author":"Gregg","year":"2018","journal-title":"Am J Kidney Dis"},{"key":"10.1016\/j.cjca.2019.06.029_bib26","doi-asserted-by":"crossref","first-page":"629","DOI":"10.7326\/0003-4819-134-8-200104170-00007","article-title":"Renal insufficiency as a predictor of cardiovascular outcomes and the impact of ramipril: the HOPE randomized trial","volume":"134","author":"Mann","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2019.06.029_bib27","doi-asserted-by":"crossref","first-page":"253","DOI":"10.1016\/S0140-6736(99)12323-7","article-title":"Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy","volume":"355","year":"2000","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2019.06.029_bib28","doi-asserted-by":"crossref","first-page":"602","DOI":"10.1001\/jama.2016.10924","article-title":"Clinical manifestations of kidney disease among US adults with diabetes, 1988-2014","volume":"316","author":"Afkarian","year":"2016","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2019.06.029_bib29","doi-asserted-by":"crossref","first-page":"861","DOI":"10.1056\/NEJMoa011161","article-title":"Effects of losartan on renal and cardiovascular outcomes in patients with type 2 diabetes and nephropathy","volume":"345","author":"Brenner","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.06.029_bib30","doi-asserted-by":"crossref","first-page":"829","DOI":"10.1016\/S0140-6736(07)61303-8","article-title":"Effects of a fixed combination of perindopril and indapamide on macrovascular and microvascular outcomes in patients with type 2 diabetes mellitus (the ADVANCE trial): a randomised controlled trial","volume":"370","author":"Patel","year":"2007","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2019.06.029_bib31","doi-asserted-by":"crossref","first-page":"370","DOI":"10.7326\/0003-4819-134-5-200103060-00009","article-title":"Should all patients with type 1 diabetes mellitus and microalbuminuria receive angiotensin-converting enzyme inhibitors? A meta-analysis of individual patient data","volume":"134","year":"2001","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2019.06.029_bib32","doi-asserted-by":"crossref","first-page":"129","DOI":"10.7326\/0003-4819-118-2-199301150-00009","article-title":"Effect of antihypertensive therapy on the kidney in patients with diabetes: a meta-regression analysis","volume":"118","author":"Kasiske","year":"1993","journal-title":"Ann Intern Med"},{"key":"10.1016\/j.cjca.2019.06.029_bib33","doi-asserted-by":"crossref","first-page":"1456","DOI":"10.1056\/NEJM199311113292004","article-title":"The effect of angiotensin-converting-enzyme inhibition on diabetic nephropathy","volume":"329","author":"Lewis","year":"1993","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.06.029_bib34","doi-asserted-by":"crossref","first-page":"24","DOI":"10.1136\/bmj.319.7201.24","article-title":"Randomised controlled trial of long term efficacy of captopril on preservation of kidney function in normotensive patients with insulin dependent diabetes and microalbuminuria","volume":"319","author":"Mathiesen","year":"1999","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2019.06.029_bib35","doi-asserted-by":"crossref","first-page":"851","DOI":"10.1056\/NEJMoa011303","article-title":"Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes","volume":"345","author":"Lewis","year":"2001","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.06.029_bib36","doi-asserted-by":"crossref","first-page":"2309","DOI":"10.1111\/j.1523-1755.2004.00653.x","article-title":"Proteinuria, a target for renoprotection in patients with type 2 diabetic nephropathy: lessons from RENAAL","volume":"65","author":"de Zeeuw","year":"2004","journal-title":"Kidney Int"},{"key":"10.1016\/j.cjca.2019.06.029_bib37","doi-asserted-by":"crossref","first-page":"145","DOI":"10.1056\/NEJM200001203420301","article-title":"Effects of an angiotensin-converting-enzyme inhibitor, ramipril, on cardiovascular events in high-risk patients","volume":"342","author":"Yusuf","year":"2000","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.06.029_bib38","doi-asserted-by":"crossref","first-page":"669","DOI":"10.1056\/NEJM199209033271001","article-title":"Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction","volume":"327","author":"Pfeffer","year":"1992","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.06.029_bib39","doi-asserted-by":"crossref","first-page":"2","DOI":"10.1093\/eurheartj\/15.suppl_B.2","article-title":"Uniformity of captopril benefit in the SAVE study: subgroup analysis","volume":"15","author":"Moye","year":"1994","journal-title":"Eur Heart J"},{"key":"10.1016\/j.cjca.2019.06.029_bib40","doi-asserted-by":"crossref","first-page":"782","DOI":"10.1016\/S0140-6736(03)14974-4","volume":"362","author":"Fox","year":"2003","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2019.06.029_bib41","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1016\/j.accreview.2005.02.062","article-title":"Angiotensin-converting-enzyme inhibition in stable coronary artery disease","volume":"14","year":"2005","journal-title":"ACC Current Journal Review"},{"key":"10.1016\/j.cjca.2019.06.029_bib42","doi-asserted-by":"crossref","first-page":"1174","DOI":"10.1016\/S0140-6736(08)61242-8","volume":"372","year":"2008","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2019.06.029_bib43","doi-asserted-by":"crossref","first-page":"2047","DOI":"10.1016\/S0140-6736(14)62459-4","article-title":"Comparative efficacy and safety of blood pressure-lowering agents in adults with diabetes and kidney disease: a network meta-analysis","volume":"385","author":"Palmer","year":"2015","journal-title":"The Lancet"},{"key":"10.1016\/j.cjca.2019.06.029_bib44","doi-asserted-by":"crossref","first-page":"f6008","DOI":"10.1136\/bmj.f6008","article-title":"Comparative effectiveness of renin-angiotensin system blockers and other antihypertensive drugs in patients with diabetes: systematic review and bayesian network meta-analysis","volume":"347","author":"Wu","year":"2013","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2019.06.029_bib45","doi-asserted-by":"crossref","first-page":"685","DOI":"10.1001\/archinte.160.5.685","article-title":"Angiotensin-converting enzyme inhibitor-associated elevations in serum creatinine: is this a cause for concern?","volume":"160","author":"Bakris","year":"2000","journal-title":"JAMA Intern Med"},{"key":"10.1016\/j.cjca.2019.06.029_bib46","doi-asserted-by":"crossref","first-page":"j791","DOI":"10.1136\/bmj.j791","article-title":"Serum creatinine elevation after renin-angiotensin system blockade and long term cardiorenal risks: cohort study","volume":"356","author":"Schmidt","year":"2017","journal-title":"BMJ"},{"key":"10.1016\/j.cjca.2019.06.029_bib47","doi-asserted-by":"crossref","first-page":"762","DOI":"10.1046\/j.1523-1755.2000.00224.x","article-title":"Long-term comparison of losartan and enalapril on kidney function in hypertensive type 2 diabetics with early nephropathy","volume":"58","author":"Lacourci\u00e8re","year":"2000","journal-title":"Kidney Int"},{"key":"10.1016\/j.cjca.2019.06.029_bib48","doi-asserted-by":"crossref","first-page":"1952","DOI":"10.1056\/NEJMoa042274","article-title":"Angiotensin-receptor blockade vs converting\u2013enzyme inhibition in type 2 diabetes and nephropathy","volume":"351","author":"Barnett","year":"2004","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.06.029_bib49","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pmed.1001971","article-title":"Cardiovascular and renal outcomes of renin-angiotensin system blockade in adult patients with diabetes mellitus: a systematic review with network meta-analyses","volume":"13","author":"Catal\u00e1-L\u00f3pez","year":"2016","journal-title":"PLoS Med"},{"key":"10.1016\/j.cjca.2019.06.029_bib50","doi-asserted-by":"crossref","first-page":"989","DOI":"10.2215\/CJN.07800811","article-title":"Long-term renal and cardiovascular outcomes in Antihypertensive and Lipid-Lowering Treatment to Prevent Heart Attack Trial (ALLHAT) participants by baseline estimated GFR","volume":"7","author":"Rahman","year":"2012","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cjca.2019.06.029_bib51","doi-asserted-by":"crossref","first-page":"1857","DOI":"10.1016\/S0140-6736(96)11445-8","article-title":"Randomised placebo-controlled trial of effect of ramipril on decline in glomerular filtration rate and risk of terminal renal failure in proteinuric, non-diabetic nephropathy. The GISEN Group (Gruppo Italiano di Studi Epidemiologici in Nefrologia)","volume":"349","year":"1997","journal-title":"Lancet"},{"key":"10.1016\/j.cjca.2019.06.029_bib52","doi-asserted-by":"crossref","first-page":"2421","DOI":"10.1001\/jama.288.19.2421","article-title":"Effect of blood pressure lowering and antihypertensive drug class on progression of hypertensive kidney diseaseresults from the AASK trial","volume":"288","author":"Wright","year":"2002","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2019.06.029_bib53","doi-asserted-by":"crossref","first-page":"2719","DOI":"10.1001\/jama.285.21.2719","article-title":"Effect of ramipril vs amlodipine on renal outcomes in hypertensive nephrosclerosis: a randomized controlled trial","volume":"285","author":"Agodoa","year":"2001","journal-title":"JAMA"},{"key":"10.1016\/j.cjca.2019.06.029_bib54","doi-asserted-by":"crossref","first-page":"1959","DOI":"10.1681\/ASN.2006101081","article-title":"Progression risk, urinary protein excretion, and treatment effects of angiotensin-converting enzyme inhibitors in nondiabetic kidney disease","volume":"18","author":"Kent","year":"2007","journal-title":"J\u00a0Am Soc Nephrol"},{"key":"10.1016\/j.cjca.2019.06.029_bib55","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1056\/NEJMoa0801317","article-title":"Telmisartan, ramipril, or both in patients at high risk for vascular events","volume":"358","year":"2008","journal-title":"N\u00a0Engl J Med"},{"key":"10.1016\/j.cjca.2019.06.029_bib56","doi-asserted-by":"crossref","first-page":"361","DOI":"10.2215\/CJN.03350708","article-title":"Design of combination angiotensin receptor blocker and angiotensin-converting enzyme inhibitor for treatment of diabetic nephropathy (VA NEPHRON-D)","volume":"4","author":"Fried","year":"2009","journal-title":"Clin J Am Soc Nephrol"},{"key":"10.1016\/j.cjca.2019.06.029_bib57","first-page":"881","article-title":"Aliskiren combined with losartan in type 2-diabetes and nephropathy-secondary publication [in Danish]","volume":"171","author":"Parving","year":"2009","journal-title":"Ugeskr Laeger"},{"key":"10.1016\/j.cjca.2019.06.029_bib58","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1186\/1756-0500-7-415","article-title":"Chronic kidney disease in US adults with type 2 diabetes: an updated national estimate of prevalence based on Kidney Disease: Improving Global Outcomes (KDIGO) staging","volume":"7","author":"Bailey","year":"2014","journal-title":"BMC Res Notes"},{"key":"10.1016\/j.cjca.2019.06.029_bib59","doi-asserted-by":"crossref","first-page":"3977","DOI":"10.1093\/ndt\/gfp511","article-title":"The impact of stopping inhibitors of the renin\u2013angiotensin system in patients with advanced chronic kidney disease","volume":"25","author":"Ahmed","year":"2010","journal-title":"Nephrol Dial Transplant"},{"key":"10.1016\/j.cjca.2019.06.029_bib60","doi-asserted-by":"crossref","DOI":"10.1371\/journal.pone.0188975","article-title":"Effects of calcium channel blockers comparing to angiotensin-converting enzyme inhibitors and angiotensin receptor blockers in patients with hypertension and chronic kidney disease stage 3 to 5 and dialysis: a systematic review and meta-analysis","volume":"12","author":"Lin","year":"2017","journal-title":"PLoS One"},{"key":"10.1016\/j.cjca.2019.06.029_bib61","first-page":"1333","article-title":"Proteinuria in adults: a diagnositc approach","volume":"62","author":"Carroll","year":"2000","journal-title":"Am Fam Phys"}],"container-title":["Canadian Journal of Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X19304672?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0828282X19304672?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,10]],"date-time":"2025-10-10T14:41:32Z","timestamp":1760107292000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0828282X19304672"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,9]]},"references-count":61,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2019,9]]}},"alternative-id":["S0828282X19304672"],"URL":"https:\/\/doi.org\/10.1016\/j.cjca.2019.06.029","relation":{},"ISSN":["0828-282X"],"issn-type":[{"value":"0828-282X","type":"print"}],"subject":[],"published":{"date-parts":[[2019,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"The Use of Renin-Angiotensin System Inhibitors in Patients With Chronic Kidney Disease","name":"articletitle","label":"Article Title"},{"value":"Canadian Journal of Cardiology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cjca.2019.06.029","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Canadian Cardiovascular Society. Published by Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}